Cargando…

Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma

CONTEXT: The diagnosis of papillary thyroid carcinoma (PTC) is based on nuclear features. These features may be present in focal areas in benign thyroid diseases and follicular adenoma (FA), leading to diagnostic difficulty. AIMS: To evaluate the expression and pattern of the distribution of cytoker...

Descripción completa

Detalles Bibliográficos
Autores principales: Bose, Debdas, Das, Ram Narayan, Chatterjee, Uttara, Banerjee, Uma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439787/
https://www.ncbi.nlm.nih.gov/pubmed/22988353
http://dx.doi.org/10.4103/0971-5851.99746
_version_ 1782243070208638976
author Bose, Debdas
Das, Ram Narayan
Chatterjee, Uttara
Banerjee, Uma
author_facet Bose, Debdas
Das, Ram Narayan
Chatterjee, Uttara
Banerjee, Uma
author_sort Bose, Debdas
collection PubMed
description CONTEXT: The diagnosis of papillary thyroid carcinoma (PTC) is based on nuclear features. These features may be present in focal areas in benign thyroid diseases and follicular adenoma (FA), leading to diagnostic difficulty. AIMS: To evaluate the expression and pattern of the distribution of cytokeratin 19 (CK19) in PTC and compare its reactivity with other neoplastic and non-neoplastic conditions to assess its potential as a useful marker for PTC. MATERIALS AND METHODS: Twenty two cases of papillary carcinoma (usual type, follicular and diffuse sclerosing variant), eight follicular adenomas, eight multinodular goiters (MNG) were collected for a period of two years and six months. Sections were taken from thyroidectomy specimens fixed in 10% buffered neutral formalin. Hematoxylin and eosin staining and immunohistochemical staining for CK19 were done using standard protocol. Results were semiquantitatively scored as follows: 1+ (<5% positively stained cells), 2+ (5-25%), 3+ (25-75%) and 4+ (>75%), and then analyzed. STATISTICAL ANALYSIS AND RESULTS: All 22 (100%) papillary carcinomas showed diffuse and strong (3+ and 4+) CK19 expression. Six out of eight (75%) FAs and four out of eight (50%) MNG were positive for CK19, but it was of weaker intensity (1+ and 2+) and focal in distribution. CONCLUSION: Focal CK19 staining may be found in benign disease, but diffuse and strong positivity is characteristic of PTC, which can be used in the diagnosis of PTC in lesions of equivocal morphological appearances.
format Online
Article
Text
id pubmed-3439787
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-34397872012-09-17 Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma Bose, Debdas Das, Ram Narayan Chatterjee, Uttara Banerjee, Uma Indian J Med Paediatr Oncol Original Article CONTEXT: The diagnosis of papillary thyroid carcinoma (PTC) is based on nuclear features. These features may be present in focal areas in benign thyroid diseases and follicular adenoma (FA), leading to diagnostic difficulty. AIMS: To evaluate the expression and pattern of the distribution of cytokeratin 19 (CK19) in PTC and compare its reactivity with other neoplastic and non-neoplastic conditions to assess its potential as a useful marker for PTC. MATERIALS AND METHODS: Twenty two cases of papillary carcinoma (usual type, follicular and diffuse sclerosing variant), eight follicular adenomas, eight multinodular goiters (MNG) were collected for a period of two years and six months. Sections were taken from thyroidectomy specimens fixed in 10% buffered neutral formalin. Hematoxylin and eosin staining and immunohistochemical staining for CK19 were done using standard protocol. Results were semiquantitatively scored as follows: 1+ (<5% positively stained cells), 2+ (5-25%), 3+ (25-75%) and 4+ (>75%), and then analyzed. STATISTICAL ANALYSIS AND RESULTS: All 22 (100%) papillary carcinomas showed diffuse and strong (3+ and 4+) CK19 expression. Six out of eight (75%) FAs and four out of eight (50%) MNG were positive for CK19, but it was of weaker intensity (1+ and 2+) and focal in distribution. CONCLUSION: Focal CK19 staining may be found in benign disease, but diffuse and strong positivity is characteristic of PTC, which can be used in the diagnosis of PTC in lesions of equivocal morphological appearances. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3439787/ /pubmed/22988353 http://dx.doi.org/10.4103/0971-5851.99746 Text en Copyright: © Indian Journal of Medical and Paediatric Oncology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Bose, Debdas
Das, Ram Narayan
Chatterjee, Uttara
Banerjee, Uma
Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma
title Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma
title_full Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma
title_fullStr Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma
title_full_unstemmed Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma
title_short Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma
title_sort cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439787/
https://www.ncbi.nlm.nih.gov/pubmed/22988353
http://dx.doi.org/10.4103/0971-5851.99746
work_keys_str_mv AT bosedebdas cytokeratin19immunoreactivityinthediagnosisofpapillarythyroidcarcinoma
AT dasramnarayan cytokeratin19immunoreactivityinthediagnosisofpapillarythyroidcarcinoma
AT chatterjeeuttara cytokeratin19immunoreactivityinthediagnosisofpapillarythyroidcarcinoma
AT banerjeeuma cytokeratin19immunoreactivityinthediagnosisofpapillarythyroidcarcinoma